DRDiplomová prácaZENDiploma thesisLF UPJŠUniverzita Pavla Jozefa Šafárika v Košiciach, Lekárska fakulta2026/2027ENPavol Jozef Šafárik University in Košice Faculty of Medicine1. IKI. interná klinika UPJŠ LF a UNLPEN1st Department of Internal Medicine76694Budúcnosť liečby a prevencie diabetu mellitus 1. typu - od inzulínových pier ku kmeňovým bunkám.2026-03-18T00:00:00.000+01:0001Vedúcidoc. MUDr. Ingrid Dravecká, PhD.ENSupervisor1NázovENThe Future of Treatment and Prevention of Type 1 Diabetes Mellitus – From Insulin Pens to Stem Cells1NázovSKBudúcnosť liečby a prevencie diabetu mellitus 1. typu - od inzulínových pier ku kmeňovým bunkám.2LiteratúraSKHogrebe NJ, Ishahak M, Millman JR. Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes. Cell Stem Cell. 2023 May 4;30(5):530-548. doi: 10.1016/j.stem.2023.04.002. PMID: 37146579; PMCID: PMC10167558. Jacobsen LM, Schatz D. Immunotherapy-Based Strategies for Treatment of Type 1 Diabetes. Horm Res Paediatr. 2025;98(4):425-434. doi: 10.1159/000542002. Epub 2024 Oct 14. PMID: 39401495; PMCID: PMC12038710.2LiteratúraENHogrebe NJ, Ishahak M, Millman JR. Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes. Cell Stem Cell. 2023 May 4;30(5):530-548. doi: 10.1016/j.stem.2023.04.002. PMID: 37146579; PMCID: PMC10167558. Jacobsen LM, Schatz D. Immunotherapy-Based Strategies for Treatment of Type 1 Diabetes. Horm Res Paediatr. 2025;98(4):425-434. doi: 10.1159/000542002. Epub 2024 Oct 14. PMID: 39401495; PMCID: PMC12038710.3CieľSKCieľom práce je analyzovať súčasné možnosti liečby diabetu mellitus 1. typu a poukázať na nové perspektívne prístupy zamerané na zlepšenie metabolickej kompenzácie, prevenciu ochorenia a potenciálnu obnovu funkcie pankreatických β-buniek pankreasu. Práca sa zameriava na vývoj inzulínovej terapie od tradičných spôsobov podávania inzulínu pomocou inzulínových pier až po moderné technologické riešenia, akými sú inzulínové pumpy, kontinuálne monitorovanie glukózy a automatizované systémy podávania inzulínu. Súčasne sa venuje možnostiam ovplyvnenia autoimunitného procesu vedúceho k deštrukcii β-buniek prostredníctvom imunoterapie a skúma potenciál regeneračnej medicíny, najmä využitie kmeňových buniek a náhrady pankreatických β-buniek. Cieľom práce je zároveň poukázať na budúce smerovanie liečby diabetu mellitus 1. typu, ktoré smeruje k personalizovanej medicíne a k terapeutickým stratégiám zameraným nielen na kontrolu glykémie, ale aj na prevenciu a možné vyliečenie ochorenia3CieľENThe aim of the thesis is to analyse the current treatment options for type 1 diabetes mellitus and to highlight new promising approaches aimed at improving metabolic control, preventing the disease, and potentially restoring the function of pancreatic β-cells. The thesis focuses on the development of insulin therapy from traditional methods of insulin administration using insulin pens to modern technological solutions such as insulin pumps, continuous glucose monitoring, and automated insulin delivery systems. It also addresses the possibilities of influencing the autoimmune process leading to the destruction of β-cells through immunotherapy and explores the potential of regenerative medicine, particularly the use of stem cells and pancreatic β-cell replacement. The thesis also aims to outline future directions in the treatment of type 1 diabetes mellitus, which are moving towards personalised medicine and therapeutic strategies focused not only on glycaemic control but also on the prevention and possible cure of the disease.6Kľúčové slováENType 1 diabetes mellitus, insulin therapy, continuous glucose monitoring, automated insulin delivery, immunotherapy, stem cell therapy, beta-cell replacement6Kľúčové slováSKdiabetes mellitus 1. typu, inzulínová terapia, kontinuálne monitorovanie glukózy, automatizované podávanie inzulínu, imunoterapia, liečba kmeňovými bunkami, náhrada beta-buniek 2026-03-18+01:0045.všeobecné lekárstvoVLvšeobecné lekárstvoENGeneral MedicineGeneral Medicine75264Changes in the therapeutic approach to the dysfunction of the thyroid gland2025-11-07T00:00:00.000+01:0001VedúciMUDr. Emil Fraenkel, PhD.ENSupervisor1NázovENChanges in the therapeutic approach to the dysfunction of the thyroid gland1NázovSKTerapia dysfunkcie štítnej žľazy - historický prehľad liečby2LiteratúraENKonstantinidou S, Konstantinidou E. The thyroid gland in ancient Greece: a historical perspective. Hormones (Athens). 2018 Jun;17(2):287-291. doi: 10.1007/s42000-018-0039-z. Epub 2018 Jun 19. PMID: 29923170.Kravets I. Hyperthyroidism: Diagnosis and Treatment. Am Fam Physician. 2016 Mar 1;93(5):363-70. PMID: 26926973. Kahaly GJ, Gottwald-Hostalek U. Use of levothyroxine in the management of hypothyroidism: A historical perspective. Front Endocrinol (Lausanne). 2022 Nov 2;13:1054983. doi: 10.3389/fendo.2022.1054983. PMID: 36407302; PMCID: PMC9666762. Burch HB, Cooper DS. Management of Graves Disease: A Review. JAMA. 2015 Dec 15;314(23):2544-54. doi: 10.1001/jama.2015.16535. Erratum in: JAMA. 2016 Feb 9;315(6):614. doi: 10.1001/jama.2016.0020. PMID: 26670972. Schübel J, Stahl A, Feldkamp J, Werner F, Uebel T, Voigt K. Thyroid Nodules: Diagnosis and Treatment in Primary Care. Dtsch Arztebl Int. 2025 Jun 27;112(13):341-347. doi: 10.3238/arztebl.m2025.0067. Erratum in: Dtsch Arztebl Int. 2025 Aug 8;122(16):438. doi: 10.3238/arztebl.m2025.9980. PMID: 40239048; PMCID: PMC12560269. Baloch Z, LiVolsi VA. Fifty years of thyroid pathology: concepts and developments. Hum Pathol. 2020 Jan;95:46-54. doi: 10.1016/j.humpath.2019.09.008. Epub 2019 Oct 22. PMID: 316546922LiteratúraSKKonstantinidou S, Konstantinidou E. The thyroid gland in ancient Greece: a historical perspective. Hormones (Athens). 2018 Jun;17(2):287-291. doi: 10.1007/s42000-018-0039-z. Epub 2018 Jun 19. PMID: 29923170.Kravets I. Hyperthyroidism: Diagnosis and Treatment. Am Fam Physician. 2016 Mar 1;93(5):363-70. PMID: 26926973. Kahaly GJ, Gottwald-Hostalek U. Use of levothyroxine in the management of hypothyroidism: A historical perspective. Front Endocrinol (Lausanne). 2022 Nov 2;13:1054983. doi: 10.3389/fendo.2022.1054983. PMID: 36407302; PMCID: PMC9666762. Burch HB, Cooper DS. Management of Graves Disease: A Review. JAMA. 2015 Dec 15;314(23):2544-54. doi: 10.1001/jama.2015.16535. Erratum in: JAMA. 2016 Feb 9;315(6):614. doi: 10.1001/jama.2016.0020. PMID: 26670972. Schübel J, Stahl A, Feldkamp J, Werner F, Uebel T, Voigt K. Thyroid Nodules: Diagnosis and Treatment in Primary Care. Dtsch Arztebl Int. 2025 Jun 27;112(13):341-347. doi: 10.3238/arztebl.m2025.0067. Erratum in: Dtsch Arztebl Int. 2025 Aug 8;122(16):438. doi: 10.3238/arztebl.m2025.9980. PMID: 40239048; PMCID: PMC12560269. Baloch Z, LiVolsi VA. Fifty years of thyroid pathology: concepts and developments. Hum Pathol. 2020 Jan;95:46-54. doi: 10.1016/j.humpath.2019.09.008. Epub 2019 Oct 22. PMID: 316546923CieľSKCieľom práce je spracovať historický prehľad liečebných prístupov k ochoreniam štítnej žľazy spojených s hypofunkciou a hyperfunkciou3CieľENThe diploma thesis aims to provide an overview of the therapeutic approach to functional disorders of the thyroid gland. 6Kľúčové slováENhyperthyroidism, hypothyroidism, thyroid gland, goitre, dysfunction of the thyroid6Kľúčové slováSK hypertyreóza, hypotyreóza, štítna žľaza, struma, dysfunkcia2025-11-07+01:0045.všeobecné lekárstvoVL-GMGeneral MedicineENGeneral MedicineGeneral Medicine75286Neuroendocrine and Cognitive Alterations in Patients with Pituitary Adenomas2025-11-17T00:00:00.000+01:0001VedúciMUDr. Mgr. Ivana Jochmanová, PhD.ENSupervisor1NázovENNeuroendocrine and Cognitive Alterations in Patients with Pituitary Adenomas1NázovSKNeuroendokrinné a kognitívne poruchy u pacientov s adenómami hypofýzy2LiteratúraEN1. Bellhouse J, Holland A, Pickard J. Psychiatric, cognitive and behavioural outcomes following craniopharyngioma and pituitary adenoma surgery. In Br J Neurosurg. 2003 Aug;17(4):319-26. 2. Pertichetti M, Serioli S, Belotti F, Mattavelli D, Schreiber A, Cappelli C, Padovani A, Gasparotti R, Nicolai P, Fontanella MM, Doglietto F. Pituitary adenomas and neuropsychological status: a systematic literature review. In Neurosurg Rev. 2020 Aug;43(4):1065-1078. doi: 10.1007/s10143-019-01134-z. 3. Yuan T, Ying J, Li C, Jin L, Kang J, Shi Y, Gui S, Liu C, Wang R, Zuo Z, Zhang Y. In Vivo Characterization of Cortical and White Matter Microstructural Pathology in Growth Hormone-Secreting Pituitary Adenoma. In Front Oncol. 2021 Apr 12:11:641359. doi: 10.3389/fonc.2021.641359. 4. Li S, Ma J, Tong Z, Jiang H, Li L, Zhang Y. Alterations of Brain Structural and Functional Connectivity Networks and Its Correlations With Cognitive Function in Patients With Hypothalamic Syndrome Following Craniopharyngioma Resection. In Brain Behav. 2025 Aug;15(8):e70730. doi: 10.1002/brb3.70730. 5. Lee M, Park MJ, Lee KH, Kim JH, Choi HJ, Kim YH. Obesity mechanism after hypothalamic damage: Cohort analysis of neuroimaging, psychological, cognitive, and clinical phenotyping data. In Front Endocrinol (Lausanne). 2023 Mar 28:14:1114409. doi: 10.3389/fendo.2023.1114409. 6. Cao C, Song J, Lin P, Yan D, Yao S, Yue J, Liu B, Lu Y, Xu G. A Longitudinal, Prospective Study to Evaluate the Effects of Treatment on the Inhibitory Control Function After Transsphenoidal Surgery for Pituitary Adenomas. In Clin EEG Neurosci. 2021 Nov;52(6):444-454. doi: 10.1177/1550059420922744. 2LiteratúraSK1. Bellhouse J, Holland A, Pickard J. Psychiatric, cognitive and behavioural outcomes following craniopharyngioma and pituitary adenoma surgery. In Br J Neurosurg. 2003 Aug;17(4):319-26. 2. Pertichetti M, Serioli S, Belotti F, Mattavelli D, Schreiber A, Cappelli C, Padovani A, Gasparotti R, Nicolai P, Fontanella MM, Doglietto F. Pituitary adenomas and neuropsychological status: a systematic literature review. In Neurosurg Rev. 2020 Aug;43(4):1065-1078. doi: 10.1007/s10143-019-01134-z. 3. Yuan T, Ying J, Li C, Jin L, Kang J, Shi Y, Gui S, Liu C, Wang R, Zuo Z, Zhang Y. In Vivo Characterization of Cortical and White Matter Microstructural Pathology in Growth Hormone-Secreting Pituitary Adenoma. In Front Oncol. 2021 Apr 12:11:641359. doi: 10.3389/fonc.2021.641359. 4. Li S, Ma J, Tong Z, Jiang H, Li L, Zhang Y. Alterations of Brain Structural and Functional Connectivity Networks and Its Correlations With Cognitive Function in Patients With Hypothalamic Syndrome Following Craniopharyngioma Resection. In Brain Behav. 2025 Aug;15(8):e70730. doi: 10.1002/brb3.70730. 5. Lee M, Park MJ, Lee KH, Kim JH, Choi HJ, Kim YH. Obesity mechanism after hypothalamic damage: Cohort analysis of neuroimaging, psychological, cognitive, and clinical phenotyping data. In Front Endocrinol (Lausanne). 2023 Mar 28:14:1114409. doi: 10.3389/fendo.2023.1114409. 6. Cao C, Song J, Lin P, Yan D, Yao S, Yue J, Liu B, Lu Y, Xu G. A Longitudinal, Prospective Study to Evaluate the Effects of Treatment on the Inhibitory Control Function After Transsphenoidal Surgery for Pituitary Adenomas. In Clin EEG Neurosci. 2021 Nov;52(6):444-454. doi: 10.1177/1550059420922744.3CieľSKCieľom je vyhodnotiť neuroendokrinné a kognitívne zmeny u pacientov s adenómami hypofýzy so zameraním na hormonálnu nerovnováhu a jej systémové účinky. Analyzovať vplyv charakteristík nádoru (typ, veľkosť, invazívnosť, hormonálna aktivita) a liečebných modalít (chirurgický zákrok, rádioterapia, farmakoterapia) na neuroendokrinné a kognitívne výsledky. Identifikovať potenciálne prediktory kognitívneho poškodenia a neuroendokrinnej dysregulácie u pacientov s adenómom hypofýzy s cieľom zlepšiť dlhodobý klinický manažment a kvalitu života.3CieľENTo evaluate neuroendocrine and cognitive alterations in patients with pituitary adenomas, focusing on hormonal imbalances and their systemic effects. To analyze the influence of tumor characteristics (type, size, invasiveness, hormonal activity) and treatment modalities (surgery, radiotherapy, pharmacotherapy) on neuroendocrine and cognitive outcomes.To identify potential predictors of cognitive impairment and neuroendocrine dysregulation in pituitary adenoma patients, aiming to improve long-term clinical management and quality of life.6Kľúčové slováENPituitary adenoma, neuroendocrine dysfunction; cognitive impairment; hormonal imbalance, quality of life; neuropsychology6Kľúčové slováSKpituitárny adenóm, neuroendokrinná dysfunkcia, kognitívne postihnutie, hormonálna dysbalancia2025-11-17+01:0045.všeobecné lekárstvoVL-GMGeneral MedicineENGeneral MedicineGeneral Medicine76652SGLT2 inhibítory: od antidiabetík k multiorgánovej protektívnej terapii2026-03-10T00:00:00.000+01:0001Vedúcidoc. MUDr. Ingrid Dravecká, PhD.ENSupervisor1NázovSKSGLT2 inhibítory: od antidiabetík k multiorgánovej protektívnej terapii1NázovENSGLT2 inhibitors: from antidiabetic drugs to multiorgan protective therapy2LiteratúraSKPreda A, Montecucco F, Carbone F, Camici GG, Lüscher TF, Kraler S, Liberale L. SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits. Cardiovasc Res. 2024 Apr 30;120(5):443-460. doi: 10.1093/cvr/cvae047. PMID: 38456601; PMCID: PMC12001887. Agarwal A, Zeng X, Li S, Rayner D, Foroutan F, Aertgeerts B, Coyac F, Farhoumand PD, Demaine A, Heen AF, Jha V, Machuve E, Nagler E, Tunnicliffe DJ, Guyatt GH, Vandvik PO, Ponte B, Agoritsas T. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for adults with chronic kidney disease: a clinical practice guideline. BMJ. 2024 Oct 1;387:e080257. doi: 10.1136/bmj-2024-080257. Erratum in: BMJ. 2024 Nov 21;387:q2605. doi: 10.1136/bmj.q2605. PMID: 39353639.2LiteratúraENPreda A, Montecucco F, Carbone F, Camici GG, Lüscher TF, Kraler S, Liberale L. SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits. Cardiovasc Res. 2024 Apr 30;120(5):443-460. doi: 10.1093/cvr/cvae047. PMID: 38456601; PMCID: PMC12001887. Agarwal A, Zeng X, Li S, Rayner D, Foroutan F, Aertgeerts B, Coyac F, Farhoumand PD, Demaine A, Heen AF, Jha V, Machuve E, Nagler E, Tunnicliffe DJ, Guyatt GH, Vandvik PO, Ponte B, Agoritsas T. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for adults with chronic kidney disease: a clinical practice guideline. BMJ. 2024 Oct 1;387:e080257. doi: 10.1136/bmj-2024-080257. Erratum in: BMJ. 2024 Nov 21;387:q2605. doi: 10.1136/bmj.q2605. PMID: 39353639.3CieľENThe aim of this thesis is to analyse the role of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus, with a focus on their mechanism of action, metabolic effects, and clinical significance. The thesis focuses not only on their impact on glycaemic control but also on their cardiovascular and renal outcomes in patients. It also includes a review of the most important clinical trials, the safety profile of these agents, and their position in current clinical guidelines. The aim is to highlight the importance of SGLT2 inhibitors as a therapy with multiorgan protective effects that extend beyond traditional antidiabetic treatment.3CieľSKCieľom tejto práce je analyzovať úlohu inhibítorov SGLT2 v liečbe diabetes mellitus 2. typu so zameraním na ich mechanizmus účinku, metabolické účinky a klinický význam. Práca sa sústreďuje na zhodnotenie ich vplyvu nielen na kontrolu glykémie, ale aj na kardiovaskulárne a renálne výsledky u pacientov. Súčasťou práce je aj prehľad najdôležitejších klinických štúdií, bezpečnostného profilu týchto liečiv a ich postavenia v súčasných odporúčaniach odborných spoločností. Cieľom je poukázať na význam SGLT2 inhibítorov ako liečby s multiorgánovým protektívnym účinkom presahujúcim rámec klasickej antidiabetickej terapie.6Kľúčové slováSKSGLT2 inhibítory, diabetes mellitus 2. typu, transport glukózy v obličkách, SGLT transportéry, renálna reabsorpcia glukózy, kardiovaskulárna protekcia, srdcové zlyhávanie, chronické ochorenie obličiek, renoprotekcia, pleiotropné účinky, klinické štúdie6Kľúčové slováENSGLT2 inhibitors, type 2 diabetes mellitus, renal glucose transport, SGLT transporters, renal glucose reabsorption, cardiovascular protection, heart failure, chronic kidney disease, renoprotection, pleiotropic effects, clinical trials.2026-03-10+01:0045.všeobecné lekárstvoVLvšeobecné lekárstvoENGeneral MedicineGeneral Medicine75263Therapeutic effects and side effects of metformin in therapy of T2DM2025-11-07T00:00:00.000+01:0001VedúciMUDr. Emil Fraenkel, PhD.ENSupervisor1NázovENTherapeutic effects and side effects of metformin in therapy of T2DM1NázovSKTerapeutické účinky a vedľajšie účinky metformínu v liečbe DM 2. typu2LiteratúraENForetz M, Guigas B, Viollet B. Metformin: update on mechanisms of action and repurposing potential. Nat Rev Endocrinol. 2023 Aug;19(8):460-476. doi: 10.1038/s41574-023-00833-4. Epub 2023 May 2. PMID: 37130947; PMCID: PMC10153049. Herman R, Kravos NA, Jensterle M, Janež A, Dolžan V. Metformin and Insulin Resistance: A Review of the Underlying Mechanisms behind Changes in GLUT4-Mediated Glucose Transport. Int J Mol Sci. 2022 Jan 23;23(3):1264. doi: 10.3390/ijms23031264. PMID: 35163187; PMCID: PMC8836112. Dutta S, Shah RB, Singhal S, Dutta SB, Bansal S, Sinha S, Haque M. Metformin: A Review of Potential Mechanism and Therapeutic Utility Beyond Diabetes. Drug Des Devel Ther. 2023 Jun 26;17:1907-1932. doi: 10.2147/DDDT.S409373. PMID: 37397787; PMCID: PMC10312383. Pavlo Petakh, Kamyshna I, Kamyshnyi A. Effects of metformin on the gut microbiota: A systematic review. Mol Metab. 2023 Nov;77:101805. doi: 10.1016/j.molmet.2023.101805. Epub 2023 Sep 9. PMID: 37696355; PMCID: PMC10518565. LaMoia TE, Shulman GI. Cellular and Molecular Mechanisms of Metformin Action. Endocr Rev. 2021 Jan 28;42(1):77-96. doi: 10.1210/endrev/bnaa023. PMID: 32897388; PMCID: PMC7846086. 2LiteratúraSKForetz M, Guigas B, Viollet B. Metformin: update on mechanisms of action and repurposing potential. Nat Rev Endocrinol. 2023 Aug;19(8):460-476. doi: 10.1038/s41574-023-00833-4. Epub 2023 May 2. PMID: 37130947; PMCID: PMC10153049. Herman R, Kravos NA, Jensterle M, Janež A, Dolžan V. Metformin and Insulin Resistance: A Review of the Underlying Mechanisms behind Changes in GLUT4-Mediated Glucose Transport. Int J Mol Sci. 2022 Jan 23;23(3):1264. doi: 10.3390/ijms23031264. PMID: 35163187; PMCID: PMC8836112. Dutta S, Shah RB, Singhal S, Dutta SB, Bansal S, Sinha S, Haque M. Metformin: A Review of Potential Mechanism and Therapeutic Utility Beyond Diabetes. Drug Des Devel Ther. 2023 Jun 26;17:1907-1932. doi: 10.2147/DDDT.S409373. PMID: 37397787; PMCID: PMC10312383. Pavlo Petakh, Kamyshna I, Kamyshnyi A. Effects of metformin on the gut microbiota: A systematic review. Mol Metab. 2023 Nov;77:101805. doi: 10.1016/j.molmet.2023.101805. Epub 2023 Sep 9. PMID: 37696355; PMCID: PMC10518565. LaMoia TE, Shulman GI. Cellular and Molecular Mechanisms of Metformin Action. Endocr Rev. 2021 Jan 28;42(1):77-96. doi: 10.1210/endrev/bnaa023. PMID: 32897388; PMCID: PMC7846086.3CieľSKCieľom práce je poskytnúť súhrn terapeutických a nežiadúcich účinkov metformínu, najmä vo vzťahu k inzulínovej rezistencii a metabolickému syndrómu z pohľadu patofyziológie a klinickej medicíny 3CieľENThe topic of the diploma thesis is the description of the relevant clinical effects and side effects of metformine related to insulin resistance,  and metabolic syndrome from the point of view of clinical, as well as pathophysiologic issues 6Kľúčové slováSKhypertyreóza, hypotyreóza, štítna žľaza, struma, dysfunkcia6Kľúčové slováENhyperthyroidism, hypothyroidism, thyroid gland, goitre, dysfunction of the thyroid2025-11-07+01:0045.všeobecné lekárstvoVL-GMGeneral MedicineENGeneral MedicineGeneral Medicine76693Type I diabetes mellitus and  long-term management of  chronic complications2026-03-18T00:00:00.000+01:0001VedúciMUDr. Emil Fraenkel, PhD.ENSupervisor1NázovENType I diabetes mellitus and  long-term management of  chronic complications1NázovSKDlhodobý manažment chronických komplikácií diabetes mellitus 1.typu2LiteratúraENTeoh IH, Elisaus P, Schofield JD. Cardiovascular Risk Management in Type 1 Diabetes. Curr Diab Rep. 2021 Aug 26;21(9):29. doi: 10.1007/s11892-021-01400-9. PMID: 34448027. Tegegne BA, Adugna A, Yenet A, Yihunie Belay W, Yibeltal Y, Dagne A, Hibstu Teffera Z, Amare GA, Abebaw D, Tewabe H, Abebe RB, Zeleke TK. A critical review on diabetes mellitus type 1 and type 2 management approaches: from lifestyle modification to current and novel targets and therapeutic agents. Front Endocrinol (Lausanne). 2024 Oct 18;15:1440456. doi: 10.3389/fendo.2024.1440456. PMID: 39493778; PMCID: PMC11527681. Dejkhamron P, Santiprabhob J, Likitmaskul S, Deerochanawong C, Rawdaree P, Tharavanij T, Reutrakul S, Kongkanka C, Suprasongsin C, Numbenjapon N, Sahakitrungruang T, Lertwattanarak R, Engkakul P, Sriwijitkamol A, Korwutthikulrangsri M, Leelawattana R, Phimphilai M, Potisat S, Khananuraksa P, Nopmaneejumruslers C, Nitiyanant W; Thai Type 1 Diabetes and Diabetes Diagnosed Before Age 30 Years Registry, Care, and Network (T1DDAR CN). Type 1 diabetes management and outcomes: A multicenter study in Thailand. J Diabetes Investig. 2021 Apr;12(4):516-526. doi: 10.1111/jdi.13390. Epub 2020 Oc Qu X, Liu C, Sun L, Sheng Z. Global Burden of Type 1 Diabetes Mellitus Related Chronic Kidney Disease among Adolescents and Young Adults, and Projections to 2035: Results from the Global Burden of Disease Study 2021. Diabetes Metab J. 2025 Jul;49(4):812-825. doi: 10.4093/dmj.2024.0544. Epub 2025 Mar 10. PMID: 40165515; PMCID: PMC12270573.t 4. Erratum in: J Diabetes Investig. 2022 Apr;13(4):749. doi: 10.1111/jdi.13794. PMID: 32815278; PMCID: PMC8015826. Oshima M, Shimizu M, Yamanouchi M, Toyama T, Hara A, Furuichi K, Wada T. Trajectories of kidney function in diabetes: a clinicopathological update. Nat Rev Nephrol. 2021 Nov;17(11):740-750. doi: 10.1038/s41581-021-00462-y. Epub 2021 Aug 6. PMID: 34363037. Rivetti G, Hursh BE, Miraglia Del Giudice E, Marzuillo P. Acute and chronic kidney complications in children with type 1 diabetes mellitus. Pediatr Nephrol. 2023 May;38(5):1449-1458. doi: 10.1007/s00467-022-05689-w. Epub 2022 Jul 27. PMID: 35896816; PMCID: PMC10060299. Melendez-Ramirez LY, Richards RJ, Cefalu WT. Complications of type 1 diabetes. Endocrinol Metab Clin North Am. 2010 Sep;39(3):625-40. doi: 10.1016/j.ecl.2010.05.009. PMID: 20723824. Chillarón JJ, Flores Le-Roux JA, Benaiges D, Pedro-Botet J. Type 1 diabetes, metabolic syndrome and cardiovascular risk. Metabolism. 2014 Feb;63(2):181-7. doi: 10.1016/j.metabol.2013.10.002. Epub 2013 Oct 24. PMID: 24274980. 2LiteratúraSKTeoh IH, Elisaus P, Schofield JD. Cardiovascular Risk Management in Type 1 Diabetes. Curr Diab Rep. 2021 Aug 26;21(9):29. doi: 10.1007/s11892-021-01400-9. PMID: 34448027. Tegegne BA, Adugna A, Yenet A, Yihunie Belay W, Yibeltal Y, Dagne A, Hibstu Teffera Z, Amare GA, Abebaw D, Tewabe H, Abebe RB, Zeleke TK. A critical review on diabetes mellitus type 1 and type 2 management approaches: from lifestyle modification to current and novel targets and therapeutic agents. Front Endocrinol (Lausanne). 2024 Oct 18;15:1440456. doi: 10.3389/fendo.2024.1440456. PMID: 39493778; PMCID: PMC11527681. Dejkhamron P, Santiprabhob J, Likitmaskul S, Deerochanawong C, Rawdaree P, Tharavanij T, Reutrakul S, Kongkanka C, Suprasongsin C, Numbenjapon N, Sahakitrungruang T, Lertwattanarak R, Engkakul P, Sriwijitkamol A, Korwutthikulrangsri M, Leelawattana R, Phimphilai M, Potisat S, Khananuraksa P, Nopmaneejumruslers C, Nitiyanant W; Thai Type 1 Diabetes and Diabetes Diagnosed Before Age 30 Years Registry, Care, and Network (T1DDAR CN). Type 1 diabetes management and outcomes: A multicenter study in Thailand. J Diabetes Investig. 2021 Apr;12(4):516-526. doi: 10.1111/jdi.13390. Epub 2020 Oc Qu X, Liu C, Sun L, Sheng Z. Global Burden of Type 1 Diabetes Mellitus Related Chronic Kidney Disease among Adolescents and Young Adults, and Projections to 2035: Results from the Global Burden of Disease Study 2021. Diabetes Metab J. 2025 Jul;49(4):812-825. doi: 10.4093/dmj.2024.0544. Epub 2025 Mar 10. PMID: 40165515; PMCID: PMC12270573.t 4. Erratum in: J Diabetes Investig. 2022 Apr;13(4):749. doi: 10.1111/jdi.13794. PMID: 32815278; PMCID: PMC8015826. Oshima M, Shimizu M, Yamanouchi M, Toyama T, Hara A, Furuichi K, Wada T. Trajectories of kidney function in diabetes: a clinicopathological update. Nat Rev Nephrol. 2021 Nov;17(11):740-750. doi: 10.1038/s41581-021-00462-y. Epub 2021 Aug 6. PMID: 34363037. Rivetti G, Hursh BE, Miraglia Del Giudice E, Marzuillo P. Acute and chronic kidney complications in children with type 1 diabetes mellitus. Pediatr Nephrol. 2023 May;38(5):1449-1458. doi: 10.1007/s00467-022-05689-w. Epub 2022 Jul 27. PMID: 35896816; PMCID: PMC10060299. Melendez-Ramirez LY, Richards RJ, Cefalu WT. Complications of type 1 diabetes. Endocrinol Metab Clin North Am. 2010 Sep;39(3):625-40. doi: 10.1016/j.ecl.2010.05.009. PMID: 20723824. Chillarón JJ, Flores Le-Roux JA, Benaiges D, Pedro-Botet J. Type 1 diabetes, metabolic syndrome and cardiovascular risk. Metabolism. 2014 Feb;63(2):181-7. doi: 10.1016/j.metabol.2013.10.002. Epub 2013 Oct 24. PMID: 24274980. 3CieľSKCieľom práce je poskytnúť ucelený pohľad na chronické komplikácie DM 1. typu z pohľadu dlhodobého manažmentu3CieľENThe diploma thesis aims to provide an overview of the long-term management of chronic complications  of type 1 diabetes mellitus 6Kľúčové slováENtype 1 diabetes mellitus, neuropathy, nefropathy, retinopathy,   cardiovascular complications, endpoints6Kľúčové slováSKdiabetes mellitus 1. Typu, neuropatia, nefropatia, retinopatia, kardiovaskulárne komplikácie, endpointy2026-03-18+01:0045.všeobecné lekárstvoVL-GMGeneral MedicineENGeneral MedicineGeneral Medicine